CL2019002800A1 - Tratamiento conjunto antineoplásico - Google Patents

Tratamiento conjunto antineoplásico

Info

Publication number
CL2019002800A1
CL2019002800A1 CL2019002800A CL2019002800A CL2019002800A1 CL 2019002800 A1 CL2019002800 A1 CL 2019002800A1 CL 2019002800 A CL2019002800 A CL 2019002800A CL 2019002800 A CL2019002800 A CL 2019002800A CL 2019002800 A1 CL2019002800 A1 CL 2019002800A1
Authority
CL
Chile
Prior art keywords
joint
antineoplastic treatment
antineoplastic
antagonist
treatment
Prior art date
Application number
CL2019002800A
Other languages
English (en)
Spanish (es)
Inventor
Markus Reschke
Dorothea Rudolph
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019002800A1 publication Critical patent/CL2019002800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CL2019002800A 2017-04-05 2019-10-01 Tratamiento conjunto antineoplásico CL2019002800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17165111 2017-04-05
EP17197930 2017-10-24

Publications (1)

Publication Number Publication Date
CL2019002800A1 true CL2019002800A1 (es) 2020-03-06

Family

ID=61899297

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002800A CL2019002800A1 (es) 2017-04-05 2019-10-01 Tratamiento conjunto antineoplásico
CL2023002946A CL2023002946A1 (es) 2017-04-05 2023-10-02 Tratamiento conjunto antineoplásico

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002946A CL2023002946A1 (es) 2017-04-05 2023-10-02 Tratamiento conjunto antineoplásico

Country Status (12)

Country Link
US (2) US20200101079A1 (enExample)
EP (2) EP4368200A3 (enExample)
JP (2) JP2020516604A (enExample)
KR (2) KR20240090927A (enExample)
CN (2) CN110505884B (enExample)
AU (1) AU2018248586A1 (enExample)
BR (1) BR112019021032A2 (enExample)
CA (1) CA3057558A1 (enExample)
CL (2) CL2019002800A1 (enExample)
MX (1) MX2019011945A (enExample)
PH (1) PH12019502291A1 (enExample)
WO (1) WO2018185135A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
SI3356411T1 (sl) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecifična protitelesa, specifična za PD1 in TIM3
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
MX2019011770A (es) 2017-04-03 2020-01-09 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
DK3606955T3 (da) 2017-04-05 2025-01-13 Hoffmann La Roche Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3
BR112020018755A2 (pt) * 2018-03-20 2021-01-05 Novartis Ag Combinações farmacêuticas
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020030016A1 (en) * 2018-08-08 2020-02-13 Ascentage Pharma (Suzhou) Co., Ltd. Combination of immunotherapies with mdm2 inhibitors
EP4603098A3 (en) * 2018-11-01 2025-09-03 Alpha Tau Medical Ltd. Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
US20220040166A1 (en) * 2018-12-11 2022-02-10 Kartos Therapeutics Methods and Compositions of Treating an Ophthalmic Condition
TW202327584A (zh) 2021-08-09 2023-07-16 德商百靈佳殷格翰國際股份有限公司 用於癌症療法之新穎口服醫藥組合物
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
WO2024133637A1 (en) * 2022-12-22 2024-06-27 Boehringer Ingelheim International Gmbh Crystalline form of an mdm2-p53 inhibitor and pharmaceutical compositions
WO2024238404A2 (en) * 2023-05-12 2024-11-21 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2008234954B9 (en) 2007-03-29 2012-02-02 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
WO2010089411A2 (en) * 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
PL3508502T3 (pl) 2013-09-20 2023-07-17 Bristol-Myers Squibb Company Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
PT3183254T (pt) 2014-08-21 2019-08-29 Boehringer Ingelheim Int Novos compostos de espiro[3h-indole-3,2¿-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
EP3317301B1 (en) * 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
TWI737635B (zh) * 2015-10-09 2021-09-01 德商百靈佳殷格翰國際股份有限公司 作為mdm2－p53抑制劑之新穎螺﹝3h－吲哚－3，2´－吡咯啶﹞－2（1h）－酮化合物及其衍生物
IL262892B2 (en) * 2016-05-18 2024-04-01 Boehringer Ingelheim Int Anti pd-1 and anti-lag3 antibodies for cancer treatment
WO2019063802A1 (en) * 2017-09-29 2019-04-04 Boehringer Ingelheim International Gmbh ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1

Also Published As

Publication number Publication date
BR112019021032A2 (pt) 2020-05-05
AU2018248586A1 (en) 2019-09-05
CL2023002946A1 (es) 2024-04-19
CN110505884A (zh) 2019-11-26
KR20240090927A (ko) 2024-06-21
JP2020516604A (ja) 2020-06-11
EP4368200A2 (en) 2024-05-15
US20200101079A1 (en) 2020-04-02
MX2019011945A (es) 2019-11-28
KR20190132687A (ko) 2019-11-28
EP3606556A1 (en) 2020-02-12
CN114949228A (zh) 2022-08-30
CA3057558A1 (en) 2018-10-11
US20230025452A1 (en) 2023-01-26
CN110505884B (zh) 2022-08-12
JP2024029009A (ja) 2024-03-05
EP4368200A3 (en) 2024-07-17
PH12019502291A1 (en) 2020-07-06
WO2018185135A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
CL2023002946A1 (es) Tratamiento conjunto antineoplásico
CL2021003353A1 (es) Tratamiento conjunto antineoplásico.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
CL2019002742A1 (es) Tratamiento conjunto antineoplásico.
CO2020004921A2 (es) Derivado de pirrolobenzodiazepina inmunoconjugado
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2020000301A1 (es) Nuevos derivados de quinolina.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
MX2016014581A (es) Composiciones de compuestos que modulan nmdar.
MX2019006950A (es) Metodos para tratar la sinaptopatia coclear.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
EA202191556A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX388780B (es) Uso de un compuesto de lignina para fertilizantes de urea con dureza mejorada.
BR112017011433A2 (pt) roda abrasiva não tecida com uma camada de barreira à umidade
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2018002638A1 (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda